SCM
UTHR icon

Superstring Capital Management’s United Therapeutics UTHR Stock Holding History

Superstring Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.89M Buy
7,172
+1,986
+38% +$1.12M 2.45% 16
2026
Q1 		$3.08M Sell
5,186
-4,265
-45% -$2.12M 2.2% 18
2025
Q4 		$4.61M Buy
+9,451
New +$4.4M 2.47% 15
2025
Q3 		– Sell
-4,874
Closed -$1.4M – 48
2025
Q2 		$1.4M Buy
+4,874
New +$1.46M 1.66% 21

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Superstring Capital Management's UTHR Position: Q2 2026 in Review

Superstring Capital Management increased its United Therapeutics (UTHR) stake by 38% in Q2 2026, buying an estimated $1.12M and bringing the position to 7,172 shares worth $3.89M. The position accounts for 2.45% of the portfolio, ranked #16.

Superstring Capital Management first reported a position in UTHR in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.61M in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Superstring Capital Management held 7,172 shares of United Therapeutics worth $3.89M as of Q2 2026.
  • Superstring Capital Management bought 1,986 United Therapeutics shares in Q2 2026, an estimated $1.12M.
  • United Therapeutics made up 2.45% of Superstring Capital Management's portfolio in Q2 2026, its #16 holding.
  • Superstring Capital Management first reported a position in United Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Superstring Capital Management's United Therapeutics position peaked at $4.61M in Q4 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.